Heat shock protein 90 (Hsp90) is a survival signaling chaperone and a cancer chemotherapeutic target. However, we have found that inhibitors of Hsp90 diminished the apoptotic response induced in leukemic cells by the antitumor alkyl-lysophospholipid analog edelfosine, which acts through lipid raft reorganization. Edelfosine treatment recruited Hsp90, c-Jun N-terminal kinase (JNK) and apoptotic molecules in lipid rafts, but not the JNK regulators apoptosis signal-regulating kinase 1 (ASK1) and Daxx, or the survival signaling molecules extracellular signal-regulated kinase (ERK) and Akt. Following edelfosine treatment, Hsp90 bound to JNK in lipid rafts and Hsp90-JNK clusters were identified at the plasma membrane by immunoelectron microscopy. Hsp90 inhibition reduced JNK protein level in lipid rafts and turned proapoptotic persistent JNK activation into a transient response in edelfosine-treated cells. Decrease in edelfosine-induced JNK activation and apoptosis by Hsp90 inhibition was prevented through proteasome inhibition, suggesting that Hsp90 inhibition diminishes apoptosis by promoting JNK protein degradation. Expression of ASK1 dominant negative mutant did not affect JNK activation and apoptosis following edelfosine treatment. These data indicate that lipid raft-recruited JNK is ASK1-independent and becomes a novel Hsp90 client protein. Our results reveal a new chaperoning role of Hsp90 on JNKmediated apoptosis following its recruitment in lipid rafts.
Introduction
Heat shock protein 90 (Hsp90) is a molecular chaperone that keeps the correct folding and function of various client proteins that promote cancer cell growth, including HER-2/Erb2, Akt, Raf-1, Bcr-Abl and mutated p53, and is overexpressed in many tumor cells (Whitesell and Lindquist, 2005) . Hsp90 is very promiscuous in its action, and proteomic and genomic studies in yeast have identified 198 putative physical interactions (Zhao et al., 2005) . Hsp90 inhibition promotes proteasomal degradation of client proteins required for tumor cell survival, and hence it has become a valuable and promising target in cancer chemotherapy, through which many relevant proteins for cancer cell survival can be targeted simultaneously (Neckers, 2002; Whitesell and Lindquist, 2005) . Hsp90 inhibitors enhance the cytotoxic action of some anticancer agents (Neckers, 2002; Solit et al., 2003; George et al., 2005) , and keep promise to reverse drug resistance.
Synthetic alkyl-lysophospholipid analogs, including the prototypic 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH 3 , edelfosine (EDLF)), represent a promising class of oral anticancer drugs that do not target the DNA but act at the membrane level and activate apoptosis (Mollinedo et al., 1993 (Mollinedo et al., , 1997 (Mollinedo et al., , 2004 Gajate and Mollinedo, 2002) . EDLF induces apoptosis more expeditiously in leukemic cells than in solid tumor cells (Nieto-Miguel et al., 2006) , through the intracellular activation of the death receptor Fas/CD95 and its recruitment, independently of its natural ligand FasL/CD95L, into lipid rafts (Gajate et al., 2000b Mollinedo, 2001, 2007) . EDLF accumulates in lipid rafts (van der Luit et al., 2002; Gajate et al., 2004) , leading to a redistribution of proteins in these membrane domains that eventually induces cell death Zaremberg et al., 2005; Gajate and Mollinedo, 2007) . EDLF was the first agent reported to promote co-clustering of Fas/CD95 and membrane rafts leading to apoptosis (Gajate et al., 2000b Gajate and Mollinedo, 2001) , representing a new way of killing tumor cells by targeting lipid rafts. Additional antitumor drugs, including resveratrol (Delmas et al., 2003) , cisplatin (Lacour et al., 2004) , aplidin and perifosine (Gajate and Mollinedo, 2007) , have been recently found to induce clustering of Fas/CD95 in lipid rafts. This has led to the notion that Fas/CD95 concentration in lipid rafts is a novel mode of action for anti-cancer drugs and a potential target in cancer chemotherapy . In addition, EDLF-induced apoptosis is mediated by c-Jun N-terminal kinase (JNK) persistent activation (Gajate et al., 1998; Ruiter et al., 1999) .
Unexpectedly, we have found here that Hsp90 inhibitors diminish the apoptotic action of EDLF in leukemic cells, suggesting a proapoptotic role of Hsp90 under these experimental conditions. Our results indicate that this effect is due to the translocation of Hsp90 to lipid rafts enriched in apoptotic signaling molecules during EDLF treatment of leukemic cells, leading to a change in its usual chaperoning properties by stabilizing proapoptotic JNK signaling. Thus, Hsp90 can act as a modulator of opposite signaling pathways depending on the microenvironment where it is located. This sets an unexpected new framework in the regulation of apoptosis via Hsp90 chaperone, which might have important consequences in combination chemotherapy.
Results
Hsp90 inhibitors diminish edelfosine-induced apoptosis in human leukemic cells EDLF induced rapidly apoptosis in human acute T-cell leukemia Jurkat cells and acute myeloid leukemia HL-60 cells, as indicated by an increase in the proportion of sub-G 1 cells (Figure 1 ). Hsp90 inhibitors, such as geldanamycin, 17-allylamino-17-demethoxygeldanamycin (17AAG) and radicicol, have been shown to potentiate tumor cell killing induced by distinct antitumor agents by inhibiting survival signaling (Whitesell and Lindquist, 2005) . However, we found that the above Hsp90 inhibitors, within the concentration range used in preclinical studies (Georgakis et al., 2006) , diminished significantly in a dose-dependent manner the apoptotic response induced by EDLF in leukemic cells (Figures 2a  and b) . These results suggest an unexpected role of Hsp90 in the induction of apoptosis in EDLF-treated leukemic cells, a rather different view from the previously assumed role of Hsp90 in potentiating survival.
Recruitment of Hsp90 and JNK in lipid rafts upon edelfosine treatment
The antitumor action of EDLF is dependent on its uptake by the target cell (Mollinedo et al., 1997; Gajate et al., 2000b) as well as on the co-clustering of Fas/CD95 and downstream signaling molecules in lipid rafts Mollinedo, 2001, 2007; Gajate et al., 2004) . The inhibition of EDLF-induced apoptosis by geldanamycin or 17AAG (Figure 2) was not due to a decreased drug uptake (0.70, 1.13, and 0.89 nmol EDLF/10 6 cells after 1-h incubation of HL-60 cells with 10 nmol [ 3 H]EDLF, in the absence and presence of geldanamycin or 17AAG, respectively). Then, we reasoned that the involvement in apoptosis of Hsp90, a widely considered survival chaperone, might reflect an alteration in the interaction of Hsp90 with its client proteins following EDLF treatment. Because EDLF induces a selective redistribution of proteins in lipid rafts Zaremberg et al., 2005) , we asked whether Hsp90 was recruited into lipid rafts following EDLF treatment in leukemic cells. Lipid rafts were isolated from Jurkat cells based on their insolubility in Triton X-100 detergent and buoyant density on discontinuous sucrose gradients. The position of membrane rafts in the gradient was determined by the presence of the ganglioside G M1 (fractions 3-6 in Figure 3a ) using the G M1 -specific ligand cholera toxin B subunit. EDLF recruited Fas/CD95, Fas-associated death-domain-containing protein (FADD) and procaspase-8 into lipid rafts, confirming previous findings , but not the survival signaling proteins Akt or extracellular signal-regulated kinase (ERK) (Figure 3a) . EDLF treatment led to the activation of caspase-8, as assessed by the appearance of the active caspase-8 cleavage form (Figure 3a ). We found a minor percentage of Hsp90 in the detergent-insoluble lipid raft region in untreated cells, albeit most of Hsp90 was located in the non-raft soluble fractions (fractions 9-12) (Figure 3a) . Interestingly, Hsp90 was translocated to lipid rafts (fractions 4-6) following EDLF treatment (Figure 3a ). This Hsp90 translocation to lipid rafts was further evidenced by proteomic analysis of lipid rafts (Figure 3b ). Pretreatment with cycloheximide inhibited protein synthesis, but did not affect total Hsp90 protein levels and EDLF-induced apoptosis and protein redistribution in lipid rafts (data not shown). Apoptosis chaperoning role of Hsp90 in lipid rafts T Nieto-Miguel et al Thus, EDLF-induced Hsp90 subcellular redistribution does not require protein synthesis. JNK was also recruited to lipid rafts following EDLF incubation (Figure 3a ), but not two major JNK activators such as apoptosis signalregulating kinase 1 (ASK1) and Daxx (Yang et al., 1997; Tobiume et al., 2001) (Figure 3a ).
Hsp90 interacts with JNK upon their recruitment into lipid rafts
Because Hsp90 and JNK were recruited in lipid rafts, and EDLF-induced apoptosis is dependent on sustained JNK activation (Gajate et al., 1998; Ruiter et al., 1999) , we hypothesized that Hsp90 might interact with unusual client proteins when present in a new scenario, favoring apoptosis and JNK activation. Persistent JNK activation is associated with apoptosis, whereas transient JNK activation is linked to proliferating and differentiating responses (Chen et al., 1996) . Hsp90 inhibitors turned sustained EDLF-induced JNK activation into a transient response in leukemic cells, decreasing JNK activation by 9-h drug-treatment (Figure 4a ), when Hsp90 and JNK were translocated to lipid rafts ( Figure 3a ). JNK protein levels were significantly reduced when Jurkat cells were incubated with the combination of 17AAG and EDLF (Figures 4b and c) . Interestingly, we found that Hsp90 bound to JNK in lipid rafts following EDLF treatment, as assessed by co-immunoprecipitation assays ( Figure 4d ). Cell treatment with 17AAG dramatically diminished the amount of JNK-Hsp90 complexes, likely through JNK degradation because the level of immunoprecipitated JNK was reduced ( Figure 4e ). These data indicate that Hsp90 regulates apoptotic signaling through its association with JNK when both molecules are accumulated in lipid rafts, preserving a proapoptotic sustained JNK activation. This also explains the inhibitory action of Hsp90 inhibitors on EDLF-induced JNK activation and apoptosis.
In addition, by immunogold double staining, we found Hsp90 and JNK co-localized in discrete clusters at the plasma membrane of EDLF-treated Jurkat cells (Figure 4f ), showing that both JNK and Hsp90 colocalize to the same area of plasma membrane. No such co-localization was detected in untreated cells (data not shown).
Furthermore, the Hsp90 inhibitor 17AAG itself did not recruit JNK to lipid rafts, but drastically reduced the JNK protein level in lipid rafts of EDLF-treated cells, though Hsp90 translocation was not inhibited (Figure 5a ). In addition, co-treatment with the proteasome inhibitor Apoptosis chaperoning role of Hsp90 in lipid rafts T Nieto-Miguel et al PS341 prevented the inhibitory effect of 17AAG on both EDLF-induced JNK activation and apoptosis (Figures 5b  and c ). Densitometric analyses of gels similar to that of Figure 5b showed that 17AAG reduced EDLF-induced JNK activation by about 40%, and co-treatment with PS341 totally prevented this inhibition (data not shown). The lane corresponding to 17AAG þ EDLF-treated cells in Figure 5b was loaded with a 33% higher protein content compared to the other lanes to achieve a similar JNK protein level, as this treatment decreased JNK levels (Figure 4b ).
Edelfosine-induced JNK activation is independent of ASK1 in leukemic cells Because ASK1, a major JNK regulator, was not recruited into lipid rafts in EDLF-treated leukemic cells, we asked for the role of ASK1 in JNK regulation and apoptosis in this system. To this aim, we transfected Jurkat cells with wild-type ASK1 or a kinase inactive mutant ASK1-K709M (Chang et al., 1998) , in which Lys 709 was changed to Met. Expression of the catalytically inactive ASK1 mutant did not inhibit EDLFinduced JNK activation and apoptosis when compared (Control) and 10 mM edelfosine-treated cells for 9 h were lysed in Triton X-100 and subjected to discontinuous sucrose density gradient centrifugation. Individual fractions were subjected to western blotting using specific antibodies. Active p18 caspase-8 cleavage form is indicated. Lipid rafts are located by G M1 (fractions 3-6). (b) Proteins from lipid rafts (pool of fractions 3-6 from a) of untreated control and edelfosine-treated Jurkat cells were subjected to two-dimensional gel electrophoresis followed by MALDI-TOF analysis. Hsp90 is indicated by an arrow. Data shown are representative of three experiments.
Apoptosis chaperoning role of Hsp90 in lipid rafts T Nieto-Miguel et al to cells transfected with empty pcDNA3.1 vector (Figures 6a and b) . These results suggest that EDLFinduced redistribution of JNK to lipid rafts renders lipid raft-located proapoptotic JNK activation independent of ASK1. In support of this view, we found that overexpression of wild-type ASK1 did not potentiate JNK activation and apoptosis (Figures 6a and b) . Similar protein expression of the wild type and mutant ASK1 was detected after transfection, as assessed by immunoblotting of the hemagglutinin (HA) epitope-tag present in the different constructs (Figure 6c) . Interestingly, overexpression of ASK1 wild type reduced EDLF-induced JNK activation and apoptosis (Figures 6a and b) , reflecting a putative Hsp90 and ASK1 competition for JNK.
Discussion
Our findings show for the first time that Hsp90 associates with JNK when both molecules are concentrated in lipid rafts, identifying JNK as a novel Hsp90 client protein. Our data lead to the novel conception that Hsp90 can chaperone apoptotic signaling by potentiating JNK persistent activation in EDLF-treated leukemic cells. As depicted in Figure 7 , our findings suggest that the concentration of Hsp90 and JNK into membrane rafts in EDLF-treated leukemic cells leads to the association of Hsp90 with JNK, preserving sustained JNK activation, hence turning this chaperone into a stabilizer of apoptotic signaling. Following Hsp90 inhibition, JNK is no longer protected by Hsp90, but degraded, likely through a proteasome-mediated way, as proteasome inhibition prevents this effect. In line with our present findings, Hsp90 has been found to associate with mixed-lineage kinase 3, involved in JNK-mediated apoptosis (Zhang et al., 2004) . These data suggest that Hsp90 is rather promiscuous in its interactions, depending on the scenario where it is located. In agreement with this view, coupling of the selective PI3K inhibitor LY294002 to geldanamycin has been reported to recruit the non-Hsp90 client protein PI3K to the geldanamycinbound Hsp90 chaperone machine, leading to a higher PI3K inhibition than did LY294002 alone (Chiosis et al., 2001) . Figure 3a from EDLF-treated cells, were immunoprecipitated (IP) with anti-JNK antibody and P3X63, as a negative control, and immunoprecipitates were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected to immunoblotting (IB) using specific antibodies against Hsp90 and JNK. (e) Extracts from untreated control cells, cells treated with 10 mM EDLF for 9 h or cells treated with 3 mM 17AAG (1 h) þ 10 mM EDLF (9 h) were immunoprecipitated (IP) with anti-JNK antibody or P3X63, as a negative control. Immunoprecipitates were subjected to SDS-PAGE and immunoblotted (IB) with specific antibodies. Experiments shown in a, b, d and e are representative of three performed. (f) Immunogold electron microscopy shows co-localization of Hsp90 (15-nm gold particles) and JNK (10-nm gold particles) to the same area of plasma membrane in EDLF-treated Jurkat cells. Gold labeling was located in clusters at the plasma membrane of EDLF-treated cells. Bars, 500 nm.
Apoptosis chaperoning role of Hsp90 in lipid rafts T Nieto-Miguel et al
Previous studies have shown a critical role for persistent JNK activation in EDLF-mediated apoptosis (Gajate et al., 1998; Ruiter et al., 1999) , EDLF being a rapid and potent JNK activator (Gajate et al., 1998; Ruiter et al., 1999) as well as a strong inducer of c-jun upregulation in leukemic cells (Mollinedo et al., 1994) .
Our data indicate that JNK and Hsp90 are concentrated in lipid rafts after treatment of leukemic cells with EDLF. In this new lipid raft location JNK is segregated from major JNK regulators, such as ASK1 and Daxx, being associated with and regulated by Hsp90. However, we cannot rule out that the association of Hsp90 with JNK may be indirect through some other lipid raft component.
Apoptosis can be triggered by an alteration of the overall balance between apoptotic and survival signals, due to a modification in the cell concentration of one of the two components of the apoptosis/survival ratio. Our previous (Gajate et al., 2000b Mollinedo, 2005, 2007) and present data suggest that this apoptosis/survival signaling balance could also be modified by a redistribution and local accumulation of apoptotic molecules in lipid rafts, setting apart apoptotic (Fas/CD95, FADD, caspase-8, JNK) from survival (ERK, Akt) signaling molecules. This concentration of apoptotic molecules, separated from survival signaling molecules, leads to a dramatic local change in the apoptosis/survival signals ratio in a specific subcellular structure that eventually triggers a cell death response.
From our present findings, it could be envisaged that Hsp90 may play a role in maintaining the stability of lipid raft-associated proapoptotic signaling upon EDLF treatment. This new role of Hsp90 sets an unexpected new framework in the regulation of apoptosis via Hsp90 chaperone, which might have important consequences in combination chemotherapy. These data suggest that Hsp90 favors EDLF-mediated apoptosis of leukemic cells, and contrary to the current rationale in cancer treatment searching for Hsp90 inhibitors, inhibition of this chaperone may lead to unwanted effects when combined with certain antitumor agents. Cell culture and transfection HL-60 and Jurkat cell lines were grown in RPMI-1640 culture medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U ml À1 penicillin, and 100 mg ml À1 streptomycin. Jurkat cells (5 Â 10 5 ), seeded in a final volume of 2.5 ml in 35-mm plates, were transfected with 6 mg of HA-tagged ASK1 wild type (pcDNA3.1-ASK1-HA) or kinase-inactive K709M mutant (pcDNA3.1-ASK1-HA-K709M), kindly provided by Dr H Ichijo (University of Tokyo, Japan), or with empty pcDNA3.1 vector (Invitrogen, San Diego, CA, USA), using the cationic polymer transfection reagent jetPEI (Qbiogene, Irvine, CA, USA). Stable transfected clones were selected by cell growth in the presence of 500 mg ml À1 G418 (Sigma) and monitored by western blotting using an anti-HA monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Materials and methods

Reagents
Apoptosis assay
Quantitation of apoptotic cells was determined by flow cytometry as the percentage of cells in the sub-G 1 region (hypodiploidy) in cell cycle analysis as previously described (Gajate et al., 2000a) .
Edelfosine uptake
Drug uptake was measured as described (Gajate et al., 2000b Mollinedo, 2001, 2007) , after incubating 1 Â 10 6 ml À1 cells with 10 mM EDLF þ 0.05 mCi ml
JNK assay A solid-phase JNK assay was carried out using a fusion protein between glutathione-S-transferase (GST) and c-Jun (amino acids 1-223) as a substrate for JNK, under conditions that enabled specific binding of JNK to the c-Jun N-terminal domain, as described previously (Gajate et al., 2000a) . The phosphorylated proteins were resolved in sodium dodecyl sulfate (SDS)-10% polyacrylamide gels followed by autoradiography. JNK activation was also assayed by western blotting analysis of phosphorylated JNK using the anti-phospho-JNK (G-7) monoclonal antibody (Santa Cruz Biotechnology).
Lipid raft isolation
Lipid rafts were isolated from 3-7 Â 10 7 cells by non-ionic detergent lysis and centrifugation on discontinuous sucrose gradients as described (Gajate and Mollinedo, 2001; Gajate et al., 2004) . Fractions (1-ml) were collected from the top of the gradient and 20 ml of each fraction were subjected to SDSpolyacrylamide gel electrophoresis (SDS-PAGE), immunoblotting and enhanced chemiluminescence detection. Location of G M1 -containing lipid rafts was determined using cholera toxin B subunit conjugated to horseradish peroxidase (Sigma). Proteins were identified using specific antibodies: anti-48-kD Fas/CD95 (C-20), anti-46-kD JNK1 (C-17), anti-60-kD Akt1/ 2 (H-136) rabbit polyclonal antibodies and anti-ERK2 
2-D gel electrophoresis and protein identification
Proteins (100 mg) from pooled fractions enriched in lipid rafts (fractions 3-6 from the sucrose gradient) were first separated according to their isoelectric point using a 3-10 pH-gradient strip (Amersham Pharmacia Biotech, Uppsala, Sweden). After isoelectrofocusing, proteins were separated according to their molecular mass using standard SDS-PAGE. Proteins were stained with SYPRO Ruby (Molecular Probes, Eugene, OR, USA) according to the manufacturer's instructions, and gels were scanned using a Fuji FLA-3000 fluorescence reader. Hsp90 was identified by in-gel digestion and peptide mass fingerprint analysis using a Bruker Ultraflex matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer (Bremen, Germany).
Co-immunoprecipitation
Jurkat cells (2 Â 10 7 ) were lysed with 200 ml of lysis buffer (30 mM Tris-HCl, pH 7.5, 1% Triton X-100, 10% glycerol, 150 mM NaCl, 2 mM Na 3 VO 4 , 2 mM PMSF) and lysates were precleared for 4 h at 4 1C with 300 ml of 20% protein A-Sepharose, and immunoprecipitated with anti-JNK antibody precoupled to protein A-Sepharose as previously described (Mollinedo et al., 2003) . Samples were subjected to SDS-PAGE, and proteins were transferred to nitrocellulose and immunoblotted. To immunoprecipate membrane raft proteins, fractions 4 and 5 (100 ml each) from the lipid raft isolation sucrose gradient were combined and used for the co-immunoprecipitation assay as above. Lysates and membrane rafts were also immunoprecipitated with P3X63 myeloma supernatant as a negative control.
Immunogold electron microscopy Jurkat cells were fixed with 2% paraformaldehyde plus 0.2% glutaraldehyde in 0.1 M PHEM buffer (60 mM PIPES, 25 mM HEPES, 2 mM MgCl 2 , 10 mM EGTA, pH 6.9) for 6 h at room temperature. Samples were dehydrated in an ethanol series and embedded in LR White resin (London Resin Company, Berkshire, UK) and ultrathin sectioned. Sections, mounted on formvar-coated nickel grids, were treated with 40 mM glycine in phosphate buffered saline/Tween (PBST) buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) for 30 min. The grids were incubated in a blocking solution containing 2% BSA in PBST for 30 min. For double immunolabeling Hsp90 and JNK proteins were detected by 1-h incubation each with anti-Hsp90 (clone-68, BD Transduction Laboratories) mouse monoclonal antibody and anti-JNK1 (C-17, Santa Cruz Biotechnology) rabbit antibody diluted 1:10 in blocking solution. Then, grids were incubated with a mixture of goat anti-mouse immunoglobulin G (IgG) coupled to 15 nm gold and goat anti-rabbit IgG linked to 10 nm gold, both diluted 1:50 in blocking solution. Between incubations, grids were rinsed in PBST and finally counterstained with 2% aqueous uranyl acetate for 20 min in the dark and examined in a Zeiss EM 900. Negative controls were prepared by omitting the primary antibody or by replacing the primary antibody by a non-relevant mouse or rabbit antibody, showing no staining of the samples.
